Latest Leadership News

Articore Group reaffirms its FY25 financial guidance while initiating a strategic review to unlock shareholder value, coinciding with the appointment of Vivek Kumar as Group CEO.

Rapid Critical Metals is dramatically increasing its land position adjacent to the Webbs Silver Project, aiming to unlock new silver discoveries and expand existing resources with a significant exploration push.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Finbar Group has fast-tracked Ronald Chan’s appointment as CEO, aiming to leverage his deep company experience to strengthen its development pipeline and growth strategy.

Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.

Torque Metals has completed its acquisition of Aston Minerals through a court-approved scheme of arrangement, issuing new shares to Aston securityholders and delisting Aston from the ASX. The combined entity will operate under Torque’s leadership with a refreshed board.

Torque Metals has completed its acquisition of Aston Minerals through court-approved schemes of arrangement, leading to Aston's delisting from the ASX and a reshaped leadership team for the combined entity.

Dateline Resources secures high-level U.S. government endorsement for its Colosseum Rare Earths Project, highlighting its strategic role in domestic critical minerals supply. The project’s significant gold resources and rare earth potential position it as a key player in America’s mineral independence efforts.

Pure Foods Tasmania has raised $100,000 through a share placement and appointed directors to new operational roles aimed at driving sales growth and improving cost efficiency.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.